This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, W. Y. Articles by Wagner, T. E. Search for Related Content PubMed PubMed Citation Articles by Chen, W. Y. Articles by Wagner, T. E.

A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis¹

Oncology Research Institute, Cancer Center, Greenville Hospital System [W. Y. C., N-y. C., R. S., T. E. W.], and Department of Microbiology and Molecular Medicine, Clemson University [W. Y. C., P. R., T. E. W.], Greenville, South Carolina 29605

Human breast cancer is the predominant malignancy and the leading cause of cancer death in women from Western societies. The cause of breast cancer is still unknown. Recently, the association between human prolactin (hPRL) activity and breast cancer has been reemphasized. Biologically active hPRL has been found to be produced locally by breast cancer cells that contain high levels of PRL receptor. A high incidence of mammary tumor growth has also been found in transgenic mice overexpressing lactogenic hormones. More importantly, it has been demonstrated that the receptors for sex steroids and PRL are coexpressed and cross-regulated. In this study, we report that we have designed and produced a hPRL antagonist, hPRL-G129R. By using cell proliferation assays, we have demonstrated that: (a) hPRL and E2 exhibited an additive stimulatory effect on human breast cancer cell (T-47D) proliferation; (b) hPRL-G129R possessed an inhibitory effect on T-47D cell proliferation; and (c) when antiestrogen (4-OH-tamoxifen) and anti-PRL (hPRL-G129R) agents were added together, an additive inhibitory effect was observed. We further investigated the mechanism of the inhibitory effects of hPRL-G129R in four hPRLR positive breast cancer cell lines. We report that hPRL-G129R is able to induce apoptosis in all four cell lines in a dose-dependent manner as determined by the Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. The apoptosis is induced within 2 h of treatment at a dose as low as 50 ng/ml. We hope that the hPRL antagonist could be used to improve the outcome of human breast cancer therapy in the near future.

This article has been cited by other articles:

				A. Dagvadorj, S.-H. Tan, Z. Liao, L. R. Cavalli, B. R. Haddad, and M. T. Nevalainen Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor Clin. Cancer Res., October 1, 2008; 14(19): 6062 - 6072. [Abstract] [Full Text] [PDF]

				N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF]

				S. S. Tworoger, A. H. Eliassen, P. Sluss, and S. E. Hankinson A Prospective Study of Plasma Prolactin Concentrations and Risk of Premenopausal and Postmenopausal Breast Cancer J. Clin. Oncol., April 20, 2007; 25(12): 1482 - 1488. [Abstract] [Full Text] [PDF]

				J. Dong, C.-H. Tsai-Morris, and M. L. Dufau A Novel Estradiol/Estrogen Receptor {alpha}-dependent Transcriptional Mechanism Controls Expression of the Human Prolactin Receptor J. Biol. Chem., July 7, 2006; 281(27): 18825 - 18836. [Abstract] [Full Text] [PDF]

				J. F. Langenheim, D. Tan, A. M. Walker, and W. Y. Chen Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists Mol. Endocrinol., March 1, 2006; 20(3): 661 - 674. [Abstract] [Full Text] [PDF]

				Z. Nouhi, N. Chughtai, S. Hartley, E. Cocolakis, J.-J. Lebrun, and S. Ali Defining the Role of Prolactin as an Invasion Suppressor Hormone in Breast Cancer Cells Cancer Res., February 1, 2006; 66(3): 1824 - 1832. [Abstract] [Full Text] [PDF]

				V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]

				S. L. Miller, J. E. DeMaria, D. O. Freier, A. M. Riegel, and C. V. Clevenger Novel Association of Vav2 and Nek3 Modulates Signaling through the Human Prolactin Receptor Mol. Endocrinol., April 1, 2005; 19(4): 939 - 949. [Abstract] [Full Text] [PDF]

				S. Bernichtein, C. Kayser, K. Dillner, S. Moulin, J. J. Kopchick, J. A. Martial, G. Norstedt, O. Isaksson, P. A. Kelly, and V. Goffin Development of Pure Prolactin Receptor Antagonists J. Biol. Chem., September 19, 2003; 278(38): 35988 - 35999. [Abstract] [Full Text] [PDF]

				M. T. Beck, N. Y. Chen, K. J. Franek, and W. Y. Chen Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer Cancer Res., July 1, 2003; 63(13): 3598 - 3604. [Abstract] [Full Text] [PDF]

				C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF]

				M. Zinger, M. McFarland, and N. Ben-Jonathan Prolactin Expression and Secretion by Human Breast Glandular and Adipose Tissue Explants J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 689 - 696. [Abstract] [Full Text] [PDF]

				G. Zhang, W. Li, L. Holle, N. Chen, and W. Y. Chen A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1196 - 1205. [Abstract] [Full Text] [PDF]

				M. D. Schroeder, J. Symowicz, and L. A. Schuler PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells Mol. Endocrinol., January 1, 2002; 16(1): 45 - 57. [Abstract] [Full Text] [PDF]